Study of Avelumab-M3814 Combinations
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 24
Summary
- Conditions
- Oncology
- Solid Tumors
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03724890
- Collaborators
- Merck KGaA, Darmstadt, Germany
- Investigators
- Study Director: Medical Responsible Merck KGaA, Darmstadt, Germany
Get Well Soon